Get the Stockscreener App
29.42
0.48%
0.14
Pre-market:
28.93
-0.49
-1.67%
Hims Hers Health Inc stock is traded at $29.42, with a volume of 8.18M.
It is up +0.48% in the last 24 hours and down -7.34% over the past month.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
See More
Previous Close:
$29.28
Open:
$29.48
24h Volume:
8.18M
Relative Volume:
0.64
Market Cap:
$6.86B
Revenue:
$2.35B
Net Income/Loss:
$128.37M
P/E Ratio:
56.35
EPS:
0.5221
Net Cash Flow:
$57.42M
1W Performance:
+5.11%
1M Performance:
-7.34%
6M Performance:
+41.17%
1Y Performance:
-46.38%
1-Day Range:
$28.57
$29.76
1-Week Range:
$27.31
$31.81
52-Week Range:
$13.74
$65.30
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, TEVA, HLN, ZTS, VTRS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
29.42 | 6.86B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | JP Morgan | Overweight |
| Mar-10-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-10-26 | Upgrade | Citigroup | Sell → Neutral |
| Mar-09-26 | Upgrade | Needham | Hold → Buy |
| Feb-24-26 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
Form 144 Hims & Hers Health For: 27 September By Investing.com - Investing.com Nigeria
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit - Morningstar
Form 4 Hims Hers Health Inc For: 26 September By Investing.com - Investing.com Nigeria
Hims & Hers CFO Okupe sells $876,846 of HIMS stock - Investing.com
Hims & Hers Health (HIMS) Unveils AI Native Weight Loss Care Platform - Yahoo Finance
Shareholders who lost money in shares of acquired Hims & - GlobeNewswire
Kaplan Fox Advises Hims & Hers Health, Inc. (NYSE: HIMS) Investor - The National Law Review
Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock DeclineInvestors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC - morningstar.com
2 Reasons to Like HIMS (and 1 Not So Much) - Yahoo Finance
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
HIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages HIMS Investors with Losses to Contact the Firm - GlobeNewswire
HIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages HIMS Investors with Losses to Contact the Firm - GlobeNewswire Inc.
HIMS Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 DeadlineHIMS - TMX Newsfile
Hims Launches AI-Native Weight Loss Care Platform Featuring Closed-Loop Action Engine and Clinical Escalation - HIT Consultant
Hims & Hers Health Inc (HIMS) Stock Up 3.1% and Still Undervalued -- GF Score: 77/100 - GuruFocus
Kaplan Fox Alerts Investors of Hims & Hers Health, Inc. (NYSE: HI - The National Law Review
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming DeadlinesHIMS - PR Newswire
Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks - MarketBeat
10 Health Care Stocks Whale Activity In Today’s Session - benzinga.com
DEADLINE ALERT for YSS, HIMS, UNCY, and PZZA: The Law - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, - GlobeNewswire
Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Hims & Hers (HIMS) Shareholder Alert: Investigation of Potential Fiduciary Duty BreachesKehoe Law Firm, P.C. - The National Law Review
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Why Better Health Demands More than a Chatbot - Hims & Hers Newsroom
Kaplan Fox Alerts Hims & Hers Health, Inc. (NYSE: HIMS) Investors - The National Law Review
Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS - PR Newswire
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today - Yahoo Finance
Hims and Hers Is Scaling Rapidly, But Management Needs To Address The Difficult Questions - Yahoo Finance
Bragar Eagel & Squire, P.C. Reminds Hims & Hers Health, - GlobeNewswire
HIMS Shareholder Alert: Investigation of Potential - GlobeNewswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Kaplan Fox Reminds Hims & Hers Health, Inc. (NYSE: HIMS) Investors With Significant Losses to Seek a Leadership Role Before Deadline on November 2, 2026 - Barchart.com
Hims & Hers Health, Inc. Securities Fraud Class Action - GlobeNewswire
Hims & Hers Suit Spotlights Health Data-Sharing Privacy Risks - Law360
Hims & Hers Health, Inc. (HIMS) Investors: November 2, 2026, Filing Deadline in Securities Fraud Class ActionContact Kessler Topaz Meltzer & Check, LLP - Morningstar
Hims & Hers Just Went Negative on Profit. Twice. - Yahoo Finance
Deadline Alert: Hims & Hers Health, Inc. (HIMS) - GlobeNewswire
HIMS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER ALERT Bernstein - GlobeNewswire
Kaplan Fox Reminds Hims & Hers Health, Inc. (NYSE: HIMS) Investor - The National Law Review
Hims and Hers Health (HIMS): The Smallcap Stocks Name Everyone's Asking About - Kalkine Media
Hims & Hers Health Inc (HIMS) Shares Surge 4.9% -- What GF Score of 77 Tells Investors - GuruFocus
THNR's Weight-Loss Index Swaps Hims & Hers for Gilead - ETF Database
Hims & Hers Health (HIMS) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline - PR Newswire
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know - Yahoo Finance
HIMS INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Hims & Hers Health, - GlobeNewswire
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):